Retinal Detachment Treatment in India and UAE | Complete Patient Guide

• WHO IS A CANDIDATE:

• Patients with confirmed rhegmatogenous retinal detachment (any stage, macular-on or macular-off)

• Patients with tractional retinal detachment secondary to proliferative diabetic retinopathy or sickle cell retinopathy

• Patients with combined tractional-rhegmatogenous detachment

• Patients with high myopia (>6 diopters) who have developed peripheral retinal breaks with associated detachment

• Patients with prior ocular trauma resulting in retinal tears or detachment

• Patients who have had failed primary retinal detachment repair (re-detachment requiring revisional surgery)

• Patients with symptomatic giant retinal tears (GRT, involving ≥90° of circumference)

• Prophylactic laser/cryotherapy candidates: patients with high-risk lattice degeneration, symptomatic horseshoe tears, or strong family history of RRD

• REQUIRED PRE-OPERATIVE DIAGNOSTICS:

• Dilated fundus examination with scleral indentation (mandatory for break localization)

• B-scan ultrasonography (essential when vitreous hemorrhage or media opacity obscures fundus view; defines extent of detachment and presence of PVR)

• Optical Coherence Tomography (OCT) — high-resolution SD-OCT or SS-OCT to assess foveal integrity, subretinal fluid height, and ellipsoid zone disruption (key predictor of visual recovery)

• Fundus fluorescein angiography (FFA) for exudative detachments to identify leakage points, vasculitis, or choroidal neovascularization

• Fundus autofluorescence (FAF) to assess RPE health and chronicity of subretinal fluid

• Systemic assessment: HbA1c and fasting glucose (diabetic patients), complete blood count, coagulation profile, ECG, and anesthesia fitness evaluation

• Axial length measurement (IOL Master or Lenstar) if combined cataract-vitrectomy surgery is planned

• CONTRAINDICATIONS / SPECIAL CONSIDERATIONS:

• Advanced proliferative vitreoretinopathy (PVR grade C or D) significantly reduces primary success rates and increases surgical complexity — not a contraindication but requires staged planning

• Active systemic anticoagulation (warfarin, apixaban, clopidogrel) — requires pre-operative bridging or cessation under medical supervision

• Uncontrolled diabetes mellitus (HbA1c >10%) increases risk of intraoperative hemorrhage and poor wound healing

• Severe cardiopulmonary disease may necessitate local/regional rather than general anesthesia planning

• Intraocular gas tamponade is an absolute contraindication to air travel until complete gas absorption — patients must confirm this with surgeon before booking return flights

• Monocular patients (only functioning eye) — surgery is strongly indicated but with heightened counseling regarding anesthetic and surgical risks

PNEUMATIC RETINOPEXY:

A minimally invasive, office-based procedure suitable for superior retinal detachments with a single break or cluster of breaks within 1–2 clock hours. The surgeon injects an expansile gas bubble (SF6 20% or C3F8 14%) intravitreally, which tamponades the causative break when the patient maintains correct head positioning (face-down or tilted, depending on break location) for 7–14 days. Laser photocoagulation or cryotherapy is applied to seal the break. No incision is made. Primary success rate: approximately 70–80% for carefully selected cases. Failure requires conversion to vitrectomy or scleral buckling. Lowest cost and fastest visual rehabilitation of all three approaches.

SCLERAL BUCKLING (SB):

The historical gold standard, particularly preferred for young phakic patients, inferior breaks, and cases without significant posterior vitreous detachment. A silicone band or sponge is sutured to the external sclera, creating an external indent that permanently closes retinal breaks by reducing vitreous traction. Subretinal fluid may be drained externally (drainage retinopexy). Breaks are treated with cryotherapy under indirect ophthalmoscopy. Anesthesia is typically general or retrobulbar block. Surgical time: 1–2 hours. SB preserves the natural lens and avoids intraocular gas in uncomplicated cases, allowing faster return to flight. Long-term complication profile includes myopic shift, diplopia from muscle manipulation, and rare extrusion of buckle element.

PARS PLANA VITRECTOMY (PPV) — PRIMARY APPROACH:

23-gauge, 25-gauge, or 27-gauge transconjunctival sutureless microincision vitrectomy systems (MIVS) are now standard, replacing the older 20-gauge platform. Three self-sealing sclerotomies (0.5–0.6 mm) are created at the pars plana, through which the light pipe, vitreous cutter, and infusion cannula are introduced. Core and peripheral vitreous are removed under wide-angle visualization systems (BIOM, Resight, or SDI). The posterior vitreous face is detached if not already separated, retinal breaks are directly identified and treated with endolaser photocoagulation, subretinal fluid is drained internally via the break or a separate retinotomy, and the vitreous cavity is then filled with tamponade agent:

• SF6 gas (20–25%): absorbed in 2–3 weeks; suitable for superior breaks

• C3F8 gas (14–16%): absorbed in 6–8 weeks; preferred for inferior breaks, macular holes

• Silicone oil (1000 or 5000 centistokes): used in complex cases (PVR, giant tears, trauma, inferior detachments); requires removal procedure at 3–6 months

Advanced adjuncts during PPV include: perfluorocarbon liquid (PFCL, e.g., perfluorodecalin) to flatten the retina intraoperatively, retinal relaxing retinotomies for PVR, and chandelier illumination for bimanual vitrectomy enabling membrane peeling. Surgical duration: 1–3 hours depending on complexity.

COMBINED PHACO-VITRECTOMY:

For patients with concurrent visually significant cataract or when silicone oil tamponade is planned (which predictably causes posterior subcapsular cataract), combined phacoemulsification cataract extraction with IOL implantation and PPV is performed in a single operative session, reducing overall anesthesia exposure and recovery time.

TRACTIONAL RETINAL DETACHMENT (TRD) — DIABETIC VITRECTOMY:

Requires PPV with bimanual delamination and segmentation of fibrovascular membranes using end-gripping forceps and curved scissors or a vitreous cutter in low-cut-rate mode. Anti-VEGF agents (bevacizumab, ranibizumab) injected 3–7 days pre-operatively reduce intraoperative hemorrhage risk from highly vascular proliferative membranes — a technique with strong evidence-base from multiple randomized trials. Intraoperative diathermy is used for hemostasis.

PROPHYLACTIC LASER PHOTOCOAGULATION / CRYOTHERAPY:

For patients with high-risk retinal findings without frank detachment — symptomatic horseshoe tears, giant retinal tears in the fellow eye, or high-risk lattice degeneration — 360-degree laser or sectoral laser retinopexy creates a demarcating chorioretinal adhesion barrier. This is typically an outpatient procedure performed under topical or peribulbar anesthesia with no recovery limitations on air travel (no gas used).

PRE-OPERATIVE PHASE (Days 1–3 after arriving in country):

• Day 1: GAF Healthcare coordinator receives patient at airport and transfers to accommodation. Emergency cases proceed directly to hospital.

• Day 1–2: Comprehensive vitreoretinal assessment at partner hospital — dilated fundus exam, B-scan ultrasonography, OCT macula and periphery, refraction, IOP measurement, FFA if indicated. Systemic pre-anesthetic workup: CBC, coagulation, renal function, ECG, chest X-ray, anesthesia consultation.

• Day 2–3: Surgeon consultation with detailed explanation of detachment characteristics, recommended surgical approach, tamponade choice, and realistic visual prognosis. Informed consent obtained. Surgeon confirms break localization, PVR grade (Machemer classification or updated Retina Society classification), and surgical plan.

• Day before surgery: Nil by mouth from midnight. Pre-operative pupil dilation drops commenced. Antibiotic prophylaxis (topical fluoroquinolone) initiated.

INTRAOPERATIVE PHASE (Day 3–5):

• Procedure performed under general anesthesia (preferred for patient comfort and surgeon control) or retrobulbar/peribulbar block with monitored sedation.

• Microincision vitrectomy (25G/27G), retinal reattachment, endolaser, and gas/oil tamponade completed in 1–3 hours.

• Recovery room observation: 2–4 hours post-operatively for IOP monitoring, pain control, and anti-emesis management.

EARLY POST-OPERATIVE PHASE (Days 1–7 post-surgery):

• Day 1 post-op: Mandatory prone or positioned head posture begins immediately for gas-tamponaded cases (strict face-down or tilted positioning for 7–14 days, minimum 45 minutes in every hour while awake).

• Day 1: First post-operative examination — intraocular pressure (IOP) check, fundus examination through dilated pupil to confirm retinal position, gas fill percentage assessment.

• Day 2–7: Topical steroid (prednisolone acetate 1% QID), topical antibiotic (moxifloxacin 0.5% QID), and topical cycloplegic (atropine 1% or cyclopentolate) commenced per protocol. IOP-lowering drops added if pressure is elevated.

• Silicone oil cases: positioning less strict; patients may be more comfortable but require return surgery in 3–6 months for oil removal.

• Nursing staff trained by GAF Healthcare partner hospitals provide head-positioning support equipment (face-down pillows, massage chairs with face holes) for accommodation.

MID-RECOVERY PHASE (Weeks 2–6):

• Week 2: Clinic review — retinal reattachment confirmed on OCT; gas bubble typically 40–70% remaining (SF6) or 80–90% (C3F8). Vision begins to improve once gas-air interface clears the visual axis; patients experience distortion and blurred vision until bubble absorbs.

• Week 3–4: SF6 bubble fully absorbed in most patients; vision stabilizing. Activity restrictions progressively lifted — no heavy lifting (>5 kg), no straining, no swimming, no contact sports.

• Week 4–6: C3F8 bubble absorbed in most patients by week 6–8. IOP monitoring continued.

• Continuous remote monitoring: GAF Healthcare facilitates teleconsultation between patient (returned home by now for silicone oil cases) and operating surgeon for OCT image sharing and IOP reporting.

FIT-TO-FLY MILESTONE:

• Pneumatic retinopexy or prophylactic laser: typically fit to fly within 1–2 weeks (confirm with surgeon; gas present = no flying).

• Scleral buckling (no gas): typically fit to fly within 2–3 weeks post-operatively.

• PPV with SF6 gas: fit to fly approximately 3–4 weeks post-operatively (once gas fully absorbed; verified by slit-lamp examination showing no gas bubble).

• PPV with C3F8 gas: fit to fly approximately 6–8 weeks post-operatively.

• Silicone oil tamponade: fit to fly within 2–4 weeks (oil does not expand with altitude); oil removal surgery required at 3–6 months.

LONG-TERM RECOVERY (Months 2–6):

• Visual acuity continues to improve for up to 12 months post-operatively in macular-off cases as photoreceptors recover.

• Spectacle prescription updated at 3 months post-operatively (refraction stable after gas/oil removal and wound healing).

• Final visual outcome assessment at 6 months; cataract development monitored in phakic patients who underwent vitrectomy (nearly universal within 2 years; planned phacoemulsification at appropriate time).